Autopsy report · NCT04874714

Efficacy and Safety Evaluation for the Treatment of Asthma and Allergic Rhinitis/Rhinoconjunctivitis

“Due to the low recruitment rate since the start of the trial”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 month before it started.
• Ran for about 2 years 5 months before it stopped.
• 18 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

Inmunotek S.L.

Sponsor type

Industry

Conditions

Allergic Rhinoconjunctivitis; Perennial Allergic Rhinitis; House Dust Mite Allergy; Pollen Allergy

Interventions

MM09-MG01(30.000-30.000); MG01(30.000); MM09(30.000); Placebo subcutaneous

Participants

18

Sites

13

Countries

Spain

Trials that died the same way

• Imatinib for Cytomegalovirus Prophylaxis and Treatment After Allogeneic Hematopoietic Stem Cell Transplantation
  “The trial is terminated due to the extremely low recruitment rate.” (83% match in meaning)
• Efficacy Study of Maintenance IT-101 Therapy for Ovarian Cancer Patients.
  “Poor trial recruitment” (83% match in meaning)
• Myloablative Cord Blood Transplant in Haematological Malignancies (MAC UCBT)
  “Trial closed early due to poor recruitment” (79% match in meaning)
• Comparing Satisfaction With a Participatory Driven Web-application and a Standard Website
  “The primary trial was stopped. Since, a feasibility study showed that recruitment was not feasible. We obtain a recruitment rate of 15 %.” (78% match in meaning)
• Study of Intraparenchymal Therapy as Adjunct Therapy in Patients With Recurrent, Resectable Glioblastoma Multiforme.
  “The decision to terminate the trial was based on the slow rate of recruitment across the programme of studies” (78% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.